Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.69 |
| ▸ | SHBG | P04278 | 7/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.43 |
| ▸ | PGR | P06401 | 4/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112542 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL12355430 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL6012294 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL6012356 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL24103283 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL24102490 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL24102641 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL24103277 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL2246608 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 | |
| SCHEMBL30339913 | 1.00 | AR (0.69) | ARSHBGSLC22A1ALDH1A1SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021252761-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN | 2011-08-11 | — | — | US | disclosed |
| US-7820642-B2 | Nandrolone 17β-carbonates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-10-26 | — | — | US | disclosed |
| US-7696190-B2 | 16Alpha-methyl or ethyl substituted estrogens | N.V. ORGANON (NL) | 2010-04-13 | — | — | US | disclosed |
| US-7696190-B2 | 16Alpha-methyl or ethyl substituted estrogens | N.V. ORGANON (NL) | 2010-04-13 | — | — | US | disclosed |
| US-20100029603-A1 | 16ALPHA-METHYL OR ETHYL SUBSTITUTED ESTROGENS | N.V. ORGANON | 2010-02-04 | — | — | US | disclosed |
| US-20100029603-A1 | 16ALPHA-METHYL OR ETHYL SUBSTITUTED ESTROGENS | N.V. ORGANON | 2010-02-04 | — | — | US | disclosed |
| EP-1846434-B1 | NANDROLONE 17ß-CARBONATES | US GOV HEALTH & HUMAN SERV (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080167283-A1 | Nandrolone 17 Beta-Carbonates | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY, DEPA (US) | 2008-07-10 | — | — | US | disclosed |
| US-7196074-B2 | Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | AR 7/4885SHBG 1/4885SLC22A1 4683/4885 |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | HSD17B11, HSD17B13, HSD3B1 | AR 518/4885SHBG 5/4885SLC22A1 2460/4885 |
| US-20080167283-A1 | Nandrolone 17 Beta-Carbonates | HSD3B1, HSD3B2, HSD17B7 | AR 90/4885SHBG 22/4885SLC22A1 706/4885 |
| US-20100029603-A1 | 16ALPHA-METHYL OR ETHYL SUBSTITUTED ESTROGENS | ESR1, CYP19A1, ESR2 | AR 21/4885SHBG 22/4885SLC22A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.